Skip to main content
Xbrane Biopharma logo

Xbrane Biopharma — Investor Relations & Filings

Ticker · XBRANE ISIN · SE0007789409 LEI · 5493008DKD05APTKQO39 ST Manufacturing
Open in API
Filings indexed 359 across all filing types
Latest filing 2024-11-19 Regulatory Filings
Country SE Sweden
Listing ST XBRANE

About Xbrane Biopharma

https://xbrane.com/en/

Xbrane Biopharma is a biotechnology company that specializes in the development of biosimilars—follow-on versions of approved biological drugs. The company's mission is to enhance the accessibility of biological treatments for serious diseases by creating more affordable alternatives. Xbrane utilizes a patented platform technology and efficient manufacturing systems, employing both bacterial and mammalian cells, to achieve lower production costs. Its development pipeline includes several biosimilar candidates, with a key product being a ranibizumab biosimilar.

Recent filings

Filing Released Lang Actions
Xbrane och Intas ingår ett globalt licens- och samutvecklingsavtal för Xbranes Nivolumab biosimilar med referens Opdivo®
Regulatory Filings Classification · 100% confidence The document announces a significant business event: a global licensing and co-development agreement between Xbrane Biopharma and Intas Pharmaceuticals regarding a Nivolumab biosimilar. It details financial terms (upfront payment, milestones, royalties) and strategic implications. This type of announcement, concerning major corporate transactions, partnerships, or financing activities, aligns best with the 'Capital/Financing Update' (CAP) category, as it involves securing funding for development and commercialization rights, or the 'Regulatory Filings' (RNS) category if it were a general disclosure. However, given the specific nature of securing rights and funding for development, CAP is a strong candidate. Alternatively, since it is a major corporate development announcement, it could also be classified as a general Regulatory Filing (RNS) if CAP is reserved strictly for equity/debt issuance. Looking at the definitions, 'CAP' covers 'Updates on company fundraising, financing activities, or capital structure changes.' Securing €10 million upfront and future royalties for development fits well under 'financing activities' related to a key asset. Furthermore, the text ends with a statement indicating it is information Xbrane is required to disclose under the EU Market Abuse Regulation, suggesting it is a mandatory regulatory disclosure. Since it is a specific, material corporate event announcement that isn't a standard financial report (10-K, IR) or an earnings release (ER), and it involves a significant financial/development agreement, RNS (Regulatory Filings - general fallback for material announcements) is often the most appropriate classification for such press releases in this context, especially when the core topic is a partnership rather than pure capital raising. Given the options, and recognizing this as a material, non-standard disclosure, RNS is the safest and most common classification for such press releases that don't fit the other specific categories like DIV, SHA, or TAR. The document length is substantial (8317 chars), so it is not an RPA.
2024-11-19 Swedish
Xbrane and Intas enter into a Global Licensing agreement to jointly develop Nivolumab biosimilar referencing Opdivo®
M&A Activity Classification · 99% confidence The document announces a 'Global Licensing and Co-Development Agreement' between Xbrane and Intas regarding a Nivolumab biosimilar. It details financial terms (upfront payment, milestones, royalties) and strategic partnership information. This type of announcement, concerning financing, partnerships, and commercial rights, fits best under the 'Capital/Financing Update' category (CAP), as it involves significant financial structuring and future revenue streams related to product development and commercialization. It is not a full financial report (10-K or IR), an earnings release (ER), or a management discussion (MDA). Since it details a major financial transaction and collaboration, CAP is the most appropriate classification.
2024-11-19 English
XBRANE BIOPHARMA PRESENTS NOMINATION COMMITTEE
Board/Management Information Classification · 99% confidence The document explicitly discusses the composition and remit of the Nomination Committee for the upcoming Annual General Meeting (AGM) in 2025. It details the appointment process based on shareholder voting power as of a specific date (September 30, 2024) and outlines the committee's responsibilities related to proposing board members, fees, and auditors for the AGM. This content is directly related to the governance and preparation for the AGM. While it is an announcement about the committee, the focus is on the structure and function related to the meeting itself, which aligns closely with AGM-related materials. Since it is not a proxy statement (PSI) or a general governance report (CGR), and it is specifically about the committee that prepares for the AGM, 'AGM Information' (AGM-R) is the most appropriate classification, as these materials are often presented or released in connection with the AGM process.
2024-10-31 English
XBRANE BIOPHARMA PRESENTERAR VALBEREDNING
AGM Information Classification · 95% confidence The document is titled "XBRANE BIOPHARMA PRESENTERAR VALBEREDNING" (Xbrane Biopharma Presents Nomination Committee). It details the composition, responsibilities, and timeline for proposing members to the Nomination Committee ahead of the 2025 Annual General Meeting (AGM). This content directly relates to the governance structure and the process leading up to shareholder voting on board members and remuneration, which falls under the scope of corporate governance information, specifically related to the AGM process. While it mentions the AGM date, the core content is about the composition of the body responsible for nominating AGM candidates. This aligns best with Governance Information (CGR) or potentially AGM Information (AGM-R). Given that it is specifically about the 'Valberedning' (Nomination Committee) composition and its mandate, CGR (Governance Information) is a strong fit, as it covers internal rules and board structure preparation. However, since the nomination committee's primary function is preparing for the AGM, and the text explicitly mentions the AGM date and shareholder proposals for the committee, it is closely related to AGM processes. Since there isn't a specific code for 'Nomination Committee Announcement', CGR is the most appropriate fit for detailed governance structure information outside of the formal proxy statement (DEF 14A/PSI). I will classify it as CGR as it details the structure and rules for board nomination preparation.
2024-10-31 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for the period January to September 2024, published by Xbrane Biopharma. It contains comprehensive financial statements, management commentary, operational updates, and performance metrics for the specified period. It is not an announcement of a report, but the report itself, containing substantive financial data. 9M 2024
2024-10-24 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is an 'Interim report January – September 2024' for Xbrane Biopharma. It contains comprehensive financial statements (income statement, balance sheet data, cash flow indicators), management's discussion and analysis (CEO's letter, business updates, portfolio status), and covers a period shorter than a full fiscal year. It meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis rather than just an announcement or certification. 9M 2024
2024-10-24 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.